Esperion Therapeutics (ESPR) Gross Profit (2019 - 2026)

Esperion Therapeutics' Gross Profit history runs 8 years deep, the most recent figure standing at $45.5 million for Q1 2026.

• Quarterly Gross Profit rose 36.09% year-over-year to $45.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $178.8 million (up 5.51% YoY) and the FY2024 annual result came in at $263.7 million, up 260.92% from the prior year.
• Gross Profit was $45.5 million for Q1 2026 at Esperion Therapeutics, down from $46.0 million in the prior quarter.
• Across five years, Gross Profit topped out at $127.7 million in Q1 2024 and bottomed at $9.7 million in Q2 2022.
• A 5-year average of $35.3 million and a median of $27.1 million in 2023 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2022 — Gross Profit tumbled 75.13% — and 2024, when it soared 907.02%.
• Esperion Therapeutics' Gross Profit stood at $14.7 million in 2022, then surged by 41.89% to $20.8 million in 2023, then jumped by 109.07% to $43.5 million in 2024, then gained by 5.84% to $46.0 million in 2025, then declined by 1.06% to $45.5 million in 2026.
• Business Quant data shows ESPR's Gross Profit at $45.5 million in Q1 2026, $46.0 million in Q3 2025, and $53.8 million in Q2 2025.